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Ketamine and propofol are two well-known, powerful anesthetic agents, yet at first sight
this appears to be their only commonality. Ketamine is a dissociative anesthetic agent,
whose main mechanism of action is considered to be N -methyl-d-aspartate (NMDA) antag-
onism; whereas propofol is a general anesthetic agent, which is assumed to primarily
potentiate currents gated by γ-aminobutyric acid type A (GABAA) receptors. However, sev-
eral experimental observations suggest a closer relationship. First, the effect of ketamine
on the electroencephalogram (EEG) is markedly changed in the presence of propofol: on
its own ketamine increases θ (4–8 Hz) and decreases α (8–13 Hz) oscillations, whereas ket-
amine induces a significant shift to beta band frequencies (13–30 Hz) in the presence of
propofol. Second, both ketamine and propofol cause inhibition of the inward pacemaker
current Ih, by binding to the corresponding hyperpolarization-activated cyclic nucleotide-
gated potassium channel 1 (HCN1) subunit. The resulting effect is a hyperpolarization of
the neuron’s resting membrane potential. Third, the ability of both ketamine and propofol
to induce hypnosis is reduced in HCN1-knockout mice. Here we show that one can theo-
retically understand the observed spectral changes of the EEG based on HCN1-mediated
hyperpolarizations alone, without involving the supposed main mechanisms of action of
these drugs through NMDA and GABAA, respectively. On the basis of our successful EEG
model we conclude that ketamine and propofol should be antagonistic to each other in
their interaction at HCN1 subunits. Such a prediction is in accord with the results of clini-
cal experiment in which it is found that ketamine and propofol interact in an infra-additive
manner with respect to the endpoints of hypnosis and immobility.
Keywords: ketamine, propofol, EEG, HCN1, neural field theory, drug interaction, anesthesia, infra-additivity
INTRODUCTION
Ketamine, a phenylcyclohexylpiperidine (PCP) derivative, is a
powerful psychoactive drug that is predominantly used as a seda-
tive and general anesthetic agent in humans and animals (Sinner
and Graf, 2008). Ketamine occurs as two stereoisomers, R(−) and
S(+), in which the latter is found to be some three to four times
more potent (White et al., 1985), but despite such differences in
potency the drug is generally made available clinically as a race-
mate (racemic mixture) that contains both stereoisomers in equal
proportion. Ketamine is classified as a dissociative agent due to
its ability to induce hallucinations and perceptual/environmental
detachment (Wolff and Winstock, 2006). Because of these prop-
erties it has become popular recreationally. At sufficiently high
doses it has been reported to induce a state of dissociation compa-
rable to that of schizophrenia, and as a consequence has found use
as a pharmacological model for psychosis (Bubenikova-Valesova
et al., 2008; Corlett et al., 2011). More recently its therapeutic
use has been re-evaluated in light of evidence suggesting that
sub-anesthetic doses may aid in the treatment of bipolar affective
disorder and major depression (Mathew et al., 2012; Murrough,
2012; Murrough et al., 2012).
While ketamine is widely believed to act principally through the
non-competitive antagonism of N -methyl-d-aspartate (NMDA)
receptor mediated glutamatergic activity (Irifune et al., 1992; Oye
et al., 1992), two significant pieces of empirical evidence have
emerged that challenge such a unitary view. Firstly, dizocilpine
(also known as MK801), an even more potent non-competitive
NMDA antagonist, produces no significant hypnotic effect (Kel-
land et al., 1993; Irifune et al., 2007). Secondly, ketamine’s effect on
spontaneous electroencephalogram (EEG) activity is qualitatively
altered when administered in the presence of propofol, a widely
used intravenous general anesthetic agent that, at clinically mean-
ingful concentrations, has little or no effect on NMDA mediated
currents. Ketamine alone has been shown to reduce spectral edge
frequencies, an effect that is driven predominately by increases
in absolute θ band (4–8 Hz) power at the expense of α band
(8–13 Hz) power (Schuttler et al., 1987; Kochs et al., 1996), see
Figure 1A. In contrast, ketamine administered in the presence of
steady state propofol levels is associated with a definite acceleration
of α band activity; increasing its peak frequency by up to 4.7 Hz
(Hayashi et al., 2007; Tsuda et al., 2007), see Figure 1C. Propo-
fol on its own roughly maintains the α peak frequency with an
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FIGURE 1 | Experimentally described EEG power spectral changes
induced by ketamine and propofol. (A) A single bolus dose of ketamine
(0.25 mg/kg) is associated with resting α activity being transiently replaced by
θ band activity. Data shown is the mean power spectral density (PSD) of EEG
recorded in three subjects from a Cz-A1/A2 (vertex-linked ears) montage.
Figure adapted and used with permission from Kochs et al. (1996). (B)
Average spectra of EEG recorded during two sequential target concentrations
of propofol in a single subject. BL=baseline, M =1.25µg/ml propofol,
H =2.5µg/ml propofol. α band EEG recorded from parietal (P4) and occipital
(O2) electrodes reveals minimal changes in peak frequency with increasing
propofol concentration. At medium propofol concentrations (M ) the α rhythm
shifts to central and frontal areas (figure not shown) without any significant
change in frequency. Figure adapted and used with permission from
Feshchenko et al. (2004). (C) Fifteen minutes after the administration of a
ketamine bolus (1 mg/kg; bold line labeled B), in the presence of a steady
state target controlled propofol level (3.5µg/ml; thin line labeled A), peak α
band EEG activity is markedly shifted to higher frequencies. Data shown is
mean PSD recorded at Fp1-A1, with an Fpz reference, from nine subjects
undergoing elective abdominal surgery. Figure used with permission from
Tsuda et al. (2007).
anteriorization of power (decrease occipital, increase frontal), see
Figure 1B; though an additional broadband “beta buzz” just above
α frequencies, “biphasic” response dynamics and smooth transi-
tions to lower frequencies can confound the picture (Schwender
et al., 1996; Kuizenga et al., 1998, 2001; Feshchenko et al., 2004;
Breshears et al., 2010; Cimenser et al., 2011). We assume here
from previous theoretical studies (Liley et al., 2003; Hutt and
Schimansky-Geier, 2008; Hutt and Longtin, 2010; Hindriks and
van Putten, 2012) that these complications can be accounted for by
mechanisms not considered in this work, in particular the promi-
nent γ-aminobutyric acid type A (GABAA) agonism of propofol
that affects dominantly inhibitory postsynaptic currents (Kita-
mura et al., 2003). Furthermore, the acceleration due to ketamine
observed by Hayashi et al. (2007) and Tsuda et al. (2007) that we
wish to describe occurred on top of a clear α rhythm at steady
propofol concentration, see Figure 1C. Thus we assume in the
following that the action of propofol is largely neutral concerning
the α peak frequency (while unspecified concerning total α band
spectral power).
Recently a number of alternative, behaviorally relevant, mole-
cular targets for ketamine action have been identified (Schnoebel
et al., 2005; Hevers et al., 2008; Chen et al., 2009). Of particu-
lar significance is the identification of hyperpolarization-activated
cyclic nucleotide-gated (HCN) potassium channel subunits as a
target for ketamine action (Chen et al., 2009). HCN subunits,
of which there are four isoforms (HCN1–4), assemble to form
a tetrameric ion channel that mediates an inward (i.e., depolariz-
ing) hyperpolarization-activated pacemaker current I h implicated
in neuronal rhythmogenesis (Biel, 2009; Biel et al., 2009). In
particular the HCN1 isoform has been identified as a molecular
substrate for the actions of ketamine (Chen et al., 2009): keta-
mine causes inhibition of HCN1-mediated I h currents, and hence
membrane hyperpolarization, in pyramidal neurons from wild-
type but not HCN1-knockout mice. The potency of ketamine to
provoke a loss of the righting reflex (the ability to regain footing
from a back position), which is a behavioral correlate of hypno-
sis, is also strongly reduced in HCN1-knockout mice. Hence a
causal relationship between ketamine-induced membrane hyper-
polarization and its clinical effects can be made. The existence of
such a causal relationship is made more likely by evidence indi-
cating that the hypnotic potency of propofol is also reduced in
HCN1-knockout mice, in approximate proportion to its ability to
inhibit HCN1-mediated membrane depolarization (Chen et al.,
2009).
It should be noted though that the hypnotic response was not
abolished entirely in HCN1-knockout mice by either ketamine
or propofol (Chen et al., 2009), thus other effects like the men-
tioned GABAA agonism will be required to fully understand the
hypnotic action of these agents. However, etomidate, which has
no effect on HCN1 channels, showed no loss of hypnotic effect
in HCN1-knockout mice (Chen et al., 2009), suggesting the spe-
cific involvement of HCN1-mediated I h currents for ketamine and
propofol. The identification of a shared molecular target for keta-
mine and propofol action could offer a new possibility to account
for the qualitatively disparate electroencephalographic effects of
ketamine alone and in the presence of propofol. On this basis we
hypothesized that by modeling the differential effects of ketamine
and propofol on neuronal membrane hyperpolarization, in the
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context of an established theory of resting EEG (Liley et al., 2002,
2010, 2011; Bojak and Liley, 2005), we would be able to describe the
observed effects on the EEG at least qualitatively. Because current
depth of anesthesia monitoring approaches are either insensitive
(Faraoni et al., 2009; Nonaka et al., 2012), or respond anomalously
(Hans et al., 2005; Sengupta et al., 2011), to the hypnotic effects
of ketamine, understanding the mechanism by which ketamine
and propofol interact electroencephalographically will ultimately
assist in the development of improved approaches to clinically
monitor the hypnotic effects of combinations of these drugs.
The combination of propofol and ketamine (often referred to
as ketofol) is becoming increasingly important in the procedural
sedation setting where rapid and effective sedation and analge-
sia, with minimal cardiorespiratory/hemodynamic compromise,
is required (Hui et al., 1995; Frizelle et al., 1997; Sakai et al., 1999;
Phillips et al., 2010).
MATERIALS AND METHODS
MODELING DRUG RESPONSE AND INTERACTIONS
The simplest pharmacodynamic model of drug effect involving
two or more agonists is that of competitive ligand-receptor bind-
ing. It is easily shown for two full agonists competing for the same
receptor binding site, that the fractional receptor occupancy θ, as a
function of the respective drug concentrations (D1, D2) is (Shafer
et al., 2008)
θ = k2D1 + k1D2
k2D1 + k1D2 + k1k2 , or (1)
θ
1− θ =
D1
k1
+ D2
k2
. (2)
For D1→∞ and/or D2→∞, one then finds θ→ 1, i.e.,
full receptor occupancy. k1, k2 > 0 are the respective drug-
receptor dissociation constants, which are equivalent to single
drug concentrations that produce 50% receptor occupancy, i.e.,
θ= 1/2. In general a pharmacodynamic effect E is assumed to
be some monotonic function of θ, i.e., E = f(θ)≡ g (D1, D2). For
a fixed effect E the locus of points (D1, D2) defines a response
isobole and E = g (D1, D2) a response surface. Now consider the
case of competitive binding and drug interaction (Greco et al.,
1995)
θ
1− θ =
D1
k1
+ D2
k2
+ ηD1D2
k1k2
, (3)
where η defines an interaction term. It can be easily demonstrated
that
θ−1
θ
< η < 0 ⇒ infra-additivity / antagonism,
η = 0 ⇒ additivity,
η > 0 ⇒ synergy.
(4)
Inspired by these considerations, we chose here to describe
the general pharmacodynamic effect of our two ligands by the
following bilinear form
E = c1D1 + c2D2 + c12D1D2. (5)
This ansatz represents the simplest extension beyond the purely
additive; and the sign of c12 then has the same interpretation
as the sign of η in Eq. 4. We will use this bilinear form below
to parameterize the dependence of the induced hyperpolariza-
tions on normalized concentrations of propofol and ketamine,
respectively.
One can however relate Eqs 3 and 5 more directly. Assume first
that the pharmacodynamic effect is directly proportional to recep-
tor occupancy, i.e., E ∝ θ. Then k1 and k2 become the respective
“half maximum effective concentrations”(EC50s) at which 50% of
the maximum response is observed for each drug applied alone.
Furthermore, assume that the receptor occupancy remains rela-
tively small θ ≈ θ/(1− θ) = D1/k1 + D2/k2 + ηD1D2/(k1k2) <
1/2, so that the effect E < Emax/2. The half-maximal inhibition
of HCN1 subunit-mediated ionic currents by racemic ketamine
occurs at a concentration of approximately 16µM (Chen et al.,
2009), which is significantly greater than the estimated minimum
free plasma concentrations of 2.9µM required to produce sur-
gical anesthesia in humans (Grant et al., 1983). Data for the
half-maximal inhibition of HCN1-mediated ionic currents by
propofol is to our knowledge not available. However, because
HCN1-knockout mice are significantly less sensitive to the effects
of propofol than wild-type ones, we can speculate that the ED50
(the “half maximum effective dose”) for unresponsiveness with
propofol in wild-type mice corresponds roughly to the half max-
imum of the neuronal changes (EC50). Chen et al. (2009) found
this to be approximately 7 mg/kg. Using the volume of distrib-
ution of 1.38 l/kg (Cox et al., 1998) in the rat (murine values
not available), EC50 is then about 5.1 mg/l or 29µM, which is
significantly greater than the minimum free plasma concentra-
tion ∼8.5µM for surgical anesthesia. Thus Dketamine/kketamine +
Dpropofol/kpropofol+ηDketamineDpropofol/(kpropofolkketamine) < 1/2
is approximately satisfied as long as η < 12 . While the Emax
for ketamine-induced membrane hyperpolarization in murine
pyramidal neurons is of the order of −4 mV, the actual value
of Emax will depend on the species and the recording condi-
tions/preparation. In the absence of any information to the con-
trary one can assume that E < Emax/2. Thus our ansatz Eq. 5 can
be considered as following from Eq. 3 under a range of reasonable
assumptions.
LILEY MODEL AND EIGENSPECTRUM CALCULATION
We base our investigation in this paper on the Liley et al.
(2002) model, which is a typical neural field model (Deco
et al., 2008; Coombes, 2010; Bressloff, 2012; Liley et al., 2012).
In Bojak and Liley (2005) 73,454 different parameter sets,
which produce biologically plausible resting state activity, were
found for this model. We use here also the “eigenspectrum”
approach introduced in Bojak and Liley (2005) to directly pre-
dict EEG power spectral densities (PSDs) from a given para-
meter set. In the following we will briefly review a few key
features of the Liley et al. (2002) model and of the eigenspec-
trum approach that will play a role for the analysis in this
paper, and refer the reader to the original reference for more
detail. The Liley et al. (2002) model can be written concisely as
follows:
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τk
∂
∂t
hk (x, t ) = hrk − hk (x, t )+
∑
l=e,i
h
eq
lk − hk (x, t )∣∣heqlk − hrk ∣∣ Ilk (x, t ) ,
(6)(
1
γlk
∂
∂t
+ 1
)2
Ilk (x, t )
= Γlk e
γlk
 N
β
lk S
max
l
1+ e
√
2[hl (x,t )−µl ]
/
σl
+Φlk (x, t )+ plk (x, t )
 ,
(7)[(
1
vlkΛlk
∂
∂t
+ 1
)2
− 3
2
1
Λ2lk
∇2
]
Φlk (x, t )
= N
α
lk S
max
l
1+ e
√
2[hl (x,t )−µl ]
/
.σl
. (8)
In all these equations l, k = e, i serve as indices for excitatory
and inhibitory neural populations, respectively, and x gives their
position on a two-dimensional cortical sheet. The mean excitatory
soma membrane potential he(x, t ) of Eq. 6 is taken to predict the
EEG. In the absence of postsynaptic inputs these potentials hk(x,
t ) decay to their resting values hrk . The inputs Ilk(x, t ) correspond
to postsynaptic potentials and are weighted by ionic driving forces
h
eq
lk − hk (x, t ), where the heqlk are the respective Nernst poten-
tials. These weights are normalized at rest to +1 (excitatory) and
−1 (inhibitory), respectively. A postsynaptic input in Eq. 7 uses
double indices to indicate source and target (for example, Iei(x,
t ) is excitatory input to an inhibitory neural population). Γlk is
the mean peak amplitude induced by a single presynaptic pulse
δ(t − t p), and 1/γlk the corresponding rise time to this peak of a
postsynaptic “α form” response I (x, t )∝ γ2te−γtΘ(t − t p), where
Θ is the Heaviside step function and δ the Dirac delta function.
Extra-cortical input is given by plk(x, t ), and is here assumed to
be shaped noise (pee), static (pei), or absent (pik). The noise repre-
sents the average of uncorrelated input to the many neurons in the
neural mass. For simplicity it is imposed only on the excitatory
extra-cortical input to excitatory neurons, which is sufficient to
generate the full dynamical range of the model. Finally, activity
is propagated cortico-cortically via Eq. 8 with a standard damped
wave equation (Jirsa and Haken, 1996; Robinson et al., 1997). The
activity propagation through Φlk(x, t ) represents a synaptic foot-
print which falls off exponentially with characteristic distance scale
Λlk, and fibers having conduction velocity νlk. Since there are no
long-range inhibitory fibers, we can set Φik≡ 0 in the following.
Short range connectivity is both excitatory and inhibitory, and is
represented by the first term in the curly brackets of Eq. 7. Note
that Eq. 8 can be improved upon (Bojak and Liley, 2010), but its
main role is in this case to include a larger variety of EEG wave-
lengths as will become apparent. Our main conclusions are not
affected even for the radical choice of an entirely homogeneous
cortex, i.e., upon removing all spatial dependence.
The eigenspectrum approach (Bojak and Liley, 2005) assumes
that Eqs 6–8 have a “fixed point” solution for a homogeneous
cortex with static pee. All variables are then linearly expanded
around this solution, and auxiliary variables I˜lk = ∂Ilk/∂t and
Φ˜ek = ∂Φek/∂t are used to turn Eqs 6–8 into 14 first order ODEs.
One can then Fourier-transform in space and time, and obtains
an equation for the 14-dimensional state vector s in the form
iωs (ω, k) = J (k2) · s (ω, k)+ P (ω, k) , (9)
where J is the Jacobian matrix and P(ω, k) contains the remainder
of the extra-cortical input, i.e., the variation of pee with subtracted
mean. Note that the only spatial derivative here is the Laplacian
in Eq. 8, hence the Fourier-transformed Jacobian is a function of
the square of wavenumber k. One can then show (Bojak and Liley,
2005) that
|he (ω, k)|2 =
∣∣∣∣∣
14∑
n=1
cn (k)
iω− λn (k)
∣∣∣∣∣
2
, (10)
where both the coefficients cn and the eigenvalues λn can be
obtained from a decomposition of the Jacobian in both left and
right eigenmatrices, and k ≡ |k|.
Furthermore, if one makes the simplifying assumption that
an EEG electrode aggregates the contributions of a disk-shaped
part of the cortical sheet with radius R, then one can compute a
prediction of the PSD as follows (Bojak and Liley, 2005)
PSD
(
f
) = 2piR2 ∞∫
0
dk
k
J21 (kR)
∣∣he (ω ≡ 2pif , k)∣∣2, (11)
where J1 is a Bessel function of the first kind. In practice we evaluate
the integral Eq. 11 numerically using a 64 point 0< ki < 14.14/cm
Gauss–Legendre quadrature, and hence need to evaluate Eq. 10 for
all these k = ki. PSDs calculated in this manner from 10 parameter
sets selected out of the 73,454 in Bojak and Liley (2005) are shown
in Figure 2. We call a solution stable if for all 64 k = ki, as well as for
homogeneous cortex k = 0 cm, the eigenvalues are such that ∀n:
<λn(k)< 0. Only for stable cases do all the approximations lead-
ing up to Eq. 11 make sense. The largest contributions to Eq. 10
arise when ω==λn(k); and if one disregards the cn(k), then the
“least stable” eigenvalue with largest <λn(k)< 0 will contribute
most.
Consider now only those λm that have non-zero frequencies
fm≡=λm(k = 0/cm)/(2pi) 6= 0: due to the selection process (Bojak
and Liley, 2005), the “least stable” λmax of these λm will have
8 Hz≤ fmax≤ 13 Hz, i.e., a frequency in the α rhythm range. If
we change from parameter set {P1} to {P2}, we can compute the
resulting frequency shift ∆f ≡ f {P2}max − f {P1}max of this eigenvalue
α frequency. We find that for the parameter changes considered
below, this “theoretical” α frequency shift ∆f estimated directly
from the eigenvalues provides a reasonable approximation for a
more“experiment-like”calculation of theα peak shift. In an exper-
iment one would typically seek the maxima of the measured PSDs
in the 8–13 Hz range, and then compute their difference in fre-
quency in order to determine an α frequency shift, cf. Figure 1C
(Hayashi et al., 2007; Tsuda et al., 2007). We can do something sim-
ilar here by evaluating the full PSDs with Eq. 11 for {P1} and {P2},
respectively, and then compute the difference of the maxima of
these theoretical predictions. However, we use the “theoretical”∆f
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FIGURE 2 | Eigenspectra of 10 parameter sets. The panels show
eigenspectra estimated with Eq. 11 from 10 different parameter sets in
Bojak and Liley (2005). These 10 sets are selected for the behavior of their α
peak frequency under hyperpolarization, see text and Figures 3B,D.
Table 1 | α peak frequency shifts predicted from the leading eigenvalue
(∆f ) and the full PSD, respectively, for the parameter sets of Figure 2.
Propofol only Ketamine only Both
P =1.2, K =0 P =0, K =1.4 P =1.2, K =1.4
∆f (Hz) PSD (Hz) ∆f (Hz) PSD (Hz) ∆f (Hz) PSD (Hz)
I 0.25 0.07 −1.42 −1.70 1.84 1.85
II 0.40 0.29 −1.60 −1.69 2.70 2.61
III 0.24 0.13 −1.37 −1.69 1.91 2.27
IV 0.45 0.37 −1.10 −0.96 2.55 2.54
V −0.20 −0.21 −1.39 −1.30 1.51 1.40
VI 0.12 −0.18 −1.00 −1.44 1.47 1.44
VII 0.10 0.16 −2.12 −2.11 2.72 2.81
VIII 0.02 −0.15 −1.33 −1.50 1.45 1.59
IX 0.20 −1.46 −1.89 −3.02 2.09 2.05
X 0.15 0.15 −1.38 −1.66 1.86 2.14
P and K are normalized propofol and ketamine concentrations, respectively.
in the following. It is much easier to compute, since it involves only
one eigendecomposition for k = 0/cm compared to 64 for k = ki
needed in the numerical PSD integration Eq. 11. Furthermore, the
“theoretical”∆f separates the change of the α peak frequency from
other changes to the spectrum. “Experiment-like” calculations of
shifts directly from local maxima in the full spectrum can be con-
founded easily by other spectral changes, and a prior subtraction
of the spectral “background” around these maxima would closely
match our “theoretical” procedure. For the parameter sets shown
in Figure 2, a comparison between “theoretical” and “experiment-
like” frequency shifts is provided by Table 1. How these shifts are
generated will be discussed in the following, but note for now that
most results are quite similar. The big discrepancies for parameter
set IX are caused precisely by a rise of the spectral “background,”
as discussed.
DRUG EFFECT PARAMETERIZATION AND SELECTION OF SETS
The effect of the action of both ketamine and propofol on HCN1
channels is to hyperpolarize the resting membrane potentials of
pyramidal (excitatory) cells (Chen et al., 2009). Consider Eq. 6 in
the absence of synaptic inputs Ilk(x, t )≡ 0, then limt→∞hk(x, t ) =
hrk . Thus h
r
e and h
r
i parameterize the excitatory and inhibitory
resting membrane potentials, respectively. In the spirit of Eq. 5 we
hence use the following ansatz:
∆hre ≡ hre
∣∣
P ,K − hre
∣∣
P=K=0 = − (a1P + a2K + a12PK )
= −∆h cos θ, (12)
∆hri ≡ hri
∣∣
P ,K − hri
∣∣
P=K=0 = − (b1P + b2K + b12PK )
= −∆h sin θ, (13)
where P, K are normalized (dimensionless) concentrations of
propofol and ketamine, respectively; and ∆hre ,∆h
r
i are changes
of the excitatory and inhibitory resting membrane potentials,
respectively, due to these drugs. For convenience we have fac-
tored out the sign corresponding to hyperpolarization, and we
have assumed that inhibitory neurons would react qualitatively
like the pyramidal cells, i.e., ∆hre ,∆h
r
i ≤ 0 mV in the consid-
ered ranges 0≤ P ≤ Pmax and 0≤K ≤K max, while quantitative
differences are expressed by potentially different coefficients. Since
the drugs applied individually lead to hyperpolarization, we must
have coefficients a1, a2, b1, b2 > 0, whereas the sign of the inter-
action coefficients a12, b12 carries the same meaning as that of
η in Eq. 4. In the following it often will be useful to express
the “Cartesian” ∆hre ,∆h
r
i ≤ 0 mV in the corresponding “polar
coordinate” form as ∆h ≡
√(
∆hre
)2 + (∆hri )2 ≥ 0 mV and
θ ≡ arctan ∆hri
∆hre
∈ [0◦, 90◦].
As a first step, we have investigated which of the 73,454 human
α rhythm sets from Bojak and Liley (2005) can be extended viably
via Eq. 12 and Eq. 13. Chen et al. (2009) found for rat pyra-
midal neurons that ∆hre = −4.0 mV for ketamine at 20µM
concentration and ∆hre = −3.7 mV for propofol at 5µM con-
centration. Assuming that in humans (and in inhibitory neu-
rons) hyperpolarizations of similar sizes occur, we varied both
hre and h
r
i away from their original values in steps of −0.05 mV
up to a hyperpolarization of −6 mV, while the remaining para-
meters were left unchanged. This leads to a grid of 121× 121
hyperpolarization combinations
(
∆hre ,∆h
r
i
)
, for which we tested
whether the changed parameter sets remain stable, i.e., we com-
puted eigendecompositions for 64+ 1 values of k and made sure
that all eigenvalues had negative real parts. We also calculated the
resulting shift in the α peak frequency as compared to the orig-
inal parameter set in the “theoretical” manner discussed above:
∆f (∆hre ,∆h
r
i ) ≡ f {
P(∆hre ,∆h
r
i )}
max − f {P(0,0)}max .
We find that of the 73,454 parameter sets only 1,627 remain
stable for all 121× 121 combinations of hyperpolarizations up
to −6 mV. This does not mean that the other parameter sets
are thereby rejected on biological or physiological grounds;
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rather their PSDs cannot be calculated with the eigenspectrum
approximation used here, but would have to be estimated from
explicit simulations with the fully non-linear Eqs 6–8. This ordi-
nary numerical procedure is several orders of magnitude slower
and hence not employed here. Figure 3A displays the average〈
∆f (∆hre ,∆h
r
i )
〉
over the 1,627 stable sets. The color bar indicates
the corresponding frequency values. We can see that in this average
there is little effect of∆hri , whereas decreasing∆h
r
e (increasing the
hyperpolarization of the pyramidal neurons) leads to an increas-
ingly negative 〈∆f 〉. The lowest average value for the 1,627 sets
in Figure 3A is 〈∆f(−6 mV, −6 mV)〉=−2.03 Hz, whereas the
highest is 〈∆f(0 mV,−6 mV)〉= 0.336 Hz.
Since more substantial increases in frequency are expected for
the interaction of ketamine and propofol (Hayashi et al., 2007;
Tsuda et al., 2007), we introduce the following cut: a set will be kept
only if for at least one of the 121× 121 hyperpolarization combi-
nations
(
∆hre ,∆h
r
i
)
we find∆f> 1.6 Hz. Similarly, since ketamine
on its own should introduce a decrease in∆f (Schuttler et al., 1987;
Kochs et al., 1996), we require that for at least one other hyper-
polarization combination ∆f<−0.8 Hz. Finally, propofol on its
own is assumed here to not change the α frequency significantly
∆f≈ 0 Hz (Schwender et al., 1996; Kuizenga et al., 1998, 2001; Fes-
hchenko et al., 2004; Breshears et al., 2010; Cimenser et al., 2011),
at least not by a HCN1-mediated mechanism, as was discussed
in the Introduction. It is more difficult to introduce a simple cut
for this property, since for small hyperpolarizations by definition
one finds∆f≈ 0 Hz. We orient ourselves here to∆hre = −3.7 mV
for propofol from Chen et al. (2009), and require that at least for
one combination with ∆hri ≤ −4.3 mV one has |∆f(−3.7 mV,≤4.3 mV)|< 0.4 Hz. Considered individually, the low frequency
cut for ketamine eliminates only 80 parameter sets, whereas the
high frequency cut for the interaction of ketamine and propo-
fol leaves only 66 parameter sets. Combining these two cuts then
leaves 64 parameter sets in total. Individually, the cut for propofol
limiting the frequency shift leaves 149 parameter sets. Combined
with the other two cuts, we arrive at 10 parameter sets. Their orig-
inal PSDs are the ones that were displayed previously in Figure 2,
and we display their parameter values in Table A1 in the Appen-
dix. We show the resulting 〈∆f 〉, now averaging over only the 10
selected sets, in Figure 3B. It is immediately apparent that there
are now three zones: for small ∆hre but large (negative) ∆h
r
i one
sees large increases in frequency, for large (negative)∆hre but small
∆hri large decreases in frequency, and in between there is a cor-
ridor with little change in frequency. This same basic structure is
found in all 10 selected sets individually.
Now we can use this structure to determine the coefficients in
Eq. 12 and Eq. 13. Starting with the case of giving ketamine only,
we can write
P = 0 : tan θK = b2
a2
. (14)
Thus the effect of increasing ketamine concentration in
the plane of hyperpolarizations is to move out along a line
through the origin with angle θK. Ketamine on its own is sup-
posed to deliver shifts to low frequencies, for which we have
set a cut ∆f<−0.8 Hz above. We now determine for every
hyperpolarization combination how many of the 10 selected para-
meter sets have ∆f
(
∆hre ,∆h
r
i
)
< −0.8 Hz. This leads to a
121× 121 grid of values between 0 and 10. In Figure 3C this
is shown by blue contour lines for 4, 7, and 10 sets fulfilling
this cut. We choose the mean of all
(
∆hre ,∆h
r
i
)
in the “maxi-
mal fulfillment” (10 sets) region (tip of blue arrow) to determine
tan θK= 0.315. Given that we do not know the dependence of
hyperpolarizations on ketamine concentrations in humans, we
choose∆hre ≡ −4 mV at K = 1 and thus consequently a2≡ 4 mV.
This implies an unknown normalization K ≡ cK /c∗K , so that
at a ketamine concentration c∗K one finds ∆hre = −4 mV in
humans. Given this choice, we have b2≡ 1.26 mV from the ket-
amine angle tan θK= 0.315. Since a2 > b2, we can now also find
K max= (6 mV)/a2= 1.5 as the largest value for the normalized
ketamine concentration for which both hyperpolarizations remain
below−6 mV.
In a similar manner we can deal with the case of propofol as
the sole drug. Then we find the angular dependence:
K = 0 : tan θP = b1
a1
. (15)
Figure 3C shows contour lines for 4, 7, and 10 parameter sets
fulfilling the cut for an α frequency shift
∣∣∆f (∆hre ,∆hri )∣∣ <
0.4 Hz, this time in green color. Since the cut was evaluated for
∆hre = −3.7 mV only to find these sets, we determine the mean
of combinations
(
∆hre ≡ −3.7 mV,∆hri
)
that have “maximal ful-
fillment” (10 sets) in order to obtain tan θP= 1.297, indicated
by the tip of the green arrow. We choose ∆hre ≡ −3.7mV at
P≡ cP/c∗P = 1, so that a1≡ 3.7 mV and at an unknown propofol
concentration c∗P one finds ∆hre = −3.7 mV in humans. Then
b1≡ 4.8 mV, and since b1 > a1 it follows that Pmax= (6 mV)/
b1= 1.25.
Finally, Figure 3C shows red contour lines for 4, 7, and 10 para-
meter sets fulfilling ∆f (∆hre ,∆h
r
i ) >1.6 Hz. Again we find the
mean of “maximal fulfillment” (10 parameter sets), as indicated
by the tip of the red arrow. These mean values are ∆h
r
e ≡ −0.177
mV and ∆h
r
i ≡ −5.903 mV in this case. We now extend to the
−6 mV hyperpolarization limit by setting ∆hmaxi ≡ −6 mV and
∆h
max
e ≡ (−6 mV)(−0.177 mV)/(−5.903 mV)=−0.180 mV. We
can now solve the following two equations
∆h
max
e = − (a1Pmax + a2Kmax + a12PmaxKmax) , (16)
∆h
max
i = − (b1Pmax + b2Kmax + b12PmaxKmax) . (17)
This will then mean that our entire hyperpolarization grid
−6 mV ≤ ∆hre ,∆hri ≤ 0 mV will be projected onto a rectan-
gular area bounded by 0≤ P ≤ Pmax and 0≤K ≤K max, respec-
tively. Solving Eq. 16 and Eq. 17 with our previous results yields
a12=−5.57 mV and b12=−1.01 mV. Figure 3D shows the pro-
jected 〈∆f(P, K )〉. Clearly the intended α frequency shifts are now
achieved: negative ones for only ketamine, none for only propofol,
and positives ones for propofol and ketamine together.
RESULTS
We have parameterized the HCN1-mediated hyperpolariza-
tions of neuron membrane potentials in order to reproduce
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FIGURE 3 | Parameterization of the hyperpolarization effects of
propofol and ketamine. (A) Shift of the α peak frequency, average
over all 1,627 sets estimated as described below Eq. 11. (B) Likewise,
but averaged over the 10 sets shown in Figure 2, which were selected
for having large up (∆f >1.6 Hz) and down (∆f <−0.8 Hz) shifts of α
peak frequency, as well as a lack of shift for some large
hyperpolarizations (|∆f (−3.7 mV, ≤4.3 mV)|<0.4 Hz). (C) Blue contours
indicate areas where 4, 7, or 10 sets have the required down-shift. A
blue arrow points to the midpoint of this area, and drug effect
parameters for Eq. 12 and Eq. 13 derived from this are listed in blue
text. Likewise, parameters are derived for up-shift in red and a lack of
shift in green. (D) These are the same results as in (B), but now plotted
against normalized propofol P and ketamine K concentrations using
the drug effect parameters found in (C).
the observed EEG effects of ketamine and propofol, and in
particular of their interaction when concurrent. The coeffi-
cients that we have obtained for Eqs 12–13 afford the fol-
lowing interpretation: pyramidal neurons react similarly to
ketamine and propofol (a1= 0.925× a2), whereas inhibitory
neurons react much more strongly to propofol than to keta-
mine (b1= 3.81× b2). Furthermore, and perhaps most interest-
ingly, there is an antagonism of ketamine and propofol (a12,
Frontiers in Computational Neuroscience www.frontiersin.org April 2013 | Volume 7 | Article 22 | 7
Bojak et al. Ketamine, propofol, and the EEG
b12 < 0), which leads to infra-additivity in the investigated effect
of HCN1-mediated hyperpolarization, cf. Eq. 4. This antagonism
is stronger in pyramidal neurons a12/(a1Pmax+ a2K max)= 4.10
b12/(b1Pmax+ b2K max), though the precise proportion depends
on the given concentrations of the drugs. Intuitively it makes sense
however that in inhibitory neurons, where one drug is much more
effective than the other, the antagonism between the drugs is less
pronounced.
To illustrate these results we look again at the “theoretical” esti-
mates of the α peak frequency in Figure 4, where we compare
now the effects of changing propofol and ketamine concentra-
tion on the 10 selected sets (red) with those computed for all
the valid 1,627 sets (gray). Note that the 1,627 sets include the
10 selected ones. Quantile bands are computed to summarize the
results for the individual parameter sets, as indicated by the leg-
end. Starting from a baseline without drugs, four phases are being
considered: first, propofol concentration is increased linearly; then
propofol is maintained at maximum concentration and ketamine
concentration is increased linearly; next propofol concentration
is decreased linearly while ketamine is maintained at maximum
concentration, and finally ketamine concentration is decreased
linearly for a return to the baseline. It should be noted that no
attempt at modeling the pharmacodynamics/pharmacokinetics
of ketamine and propofol drug action beyond drug interaction
has been made here. Furthermore, the eigenspectrum approach
assumes that the system has reached equilibrium for the given
parameters. Thus every single fmax(P, K ) predicted here, and con-
sequently every single quantile band value, represents a “steady
state” result for that particular drug concentration combination.
Hence one can for example view Figure 4 from right to left, begin-
ning with an increase in ketamine concentration, followed by an
increase in ketamine at maximum propofol concentration, and so
forth.
Comparing now the red with the gray quantile bands, we see
that our cuts selected sets that react particularly dramatically to
the concurrence of propofol and ketamine (phases 2 and 3), while
FIGURE 4 | Estimated α peak frequency shifts. Shifts of the α peak
frequency for normalized propofol P and ketamine K concentrations
estimated as described below Eq. 11, using the hyperpolarizations in
Eq. 12 and Eq. 13. Either all 1,627 (gray) or the 10 selected sets (red)
are used to compute quantile bands, as indicated by the legend. The
median value is shown by a thick black or red line, respectively. There
are four phases of drug variation, as indicated by the titles and dotted
lines, quantified by bars below the main panel: first, P =0→1.2
linearly, while K =0. Then K =0→1.4 linearly, while P =1.2. Next
P =1.2→0, while K =1.4. Finally, K =1.4→0, while P =0. No
pharmacodynamics has been modeled here, so every (P, K )
combination yields an independent “steady state” result. Hence for
example an increase of P at high K is shown by the third phase
viewed from right to left.
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being unresponsive to propofol alone (phase 1). Nevertheless, it is
not the case that the results for the 1,627 sets show a totally diver-
gent response pattern. In fact, the median rise of estimated α peak
frequency in phase 2 (upon introducing ketamine at maximum
propofol concentration) is comparable: 1.88 Hz for the selected
sets (from 11.48 to 13.36 Hz) vs. 1.56 Hz for all sets (from 9.37 to
10.93 Hz). Thus the predicted boost of α peak frequencies due
to the interaction between ketamine and propofol is a robust
result for all sets given our drug effect parameterization, which
is infra-additive concerning HCN1-mediated hyperpolarization.
The main difference appears to be rather that the α peak fre-
quencies of the selected sets do not react significantly to propofol,
whereas they are similar to all other sets in the reaction to ketamine
and the interaction between these drugs.
Turning to results for full PSDs from Eq. 11, we will consider
the 10 selected sets only due to the higher computational demands.
Figure 5 shows results for one individual set (Set III of Figure 2)
under three variations of drug concentration. In Figure 5A we
see that as desired and estimated, the α peak frequency stays
roughly the same during propofol anesthesia (Schwender et al.,
1996; Kuizenga et al., 1998, 2001; Feshchenko et al., 2004; Breshears
et al., 2010; Cimenser et al., 2011). The damping seen here would
be more characteristic of occipital than frontal regions, though
other processes in particular related to the GABAA agonism could
modify these results. The “theoretical” ∆f= 0.24 Hz at P = 1.2 is
larger than the “experiment-like” shift of 0.13 Hz. In Figure 5B
we can see the reaction to increasing ketamine concentration. As
expected, the α peak gets shifted to lower frequencies. The “the-
oretical” ∆f=−1.37 Hz estimate at K = 1.4 is somewhat lower
than the “experiment-like” shift of the local maxima of the PSDs
of −1.69 Hz. While the α oscillations get dampened, they con-
tribute to a net increase in the θ frequency range (Schuttler et al.,
1987; Kochs et al., 1996) thanks to their downward frequency shift.
But one sees also a general rise in power at lower frequencies.
Figure 5C shows that adding ketamine in the presence of high
doses of propofol leads to a shift of the α peak into the beta band,
as observed by Hayashi et al. (2007) and Tsuda et al. (2007). The
“theoretical” ∆f= 1.91 Hz at P = 1.2 and K = 1.4 is smaller than
the “experiment-like” shift of 2.27 Hz. We predict here an increase
in power, unlike the experiment, which observed a small but sig-
nificant reduction, and our frequency shift of 2.27 Hz is less than
half the observed 4.7 Hz. But this could be explained easily by
the missing GABAA and NMDA mechanisms, or the precise cir-
cumstances of the experiment. A bolus of ketamine was given by
intravenous injection in the experiment, whereas here we calcu-
late “steady state” results. Furthermore, while the frequency shifts
from our “theoretical” ∆f method are largely in agreement with
those obtained from the local α maxima of the PSDs, they do not
A B
C D
FIGURE 5 | Power spectral densities for Set III under drug variations.
(A) PSDs for increasing normalized propofol concentration from none
(thinnest green line) to 1.2 (thickest green line). (B) PSDs for increasing
normalized ketamine concentration from none (thinnest blue line) to 1.4
(thickest blue line). (C) PSDs for increasing normalized ketamine concentration
from none (thinnest red line) to 1.4 (thickest red line), while normalized
propofol concentration is held constant at 1.2. (D) Comparison of the PSDs
representing the highest normalized concentrations from (A) in green, (B) in
blue, and (C) in red. The black curve is the PSD without drugs. In all four
panels the dotted line represents the position of the α peak of this curve.
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agree perfectly – in spite of both being derived using the same
eigenspectrum technique. The difference is that by looking at the
maxima the results are influenced by changes to the overall spec-
trum, which provide the “background” on which the α resonance
sits. Table 1 gives∆f and “experiment-like”α peak frequency shifts
for the 10 sets at the three highlighted drug concentrations.
Finally, in Figure 6 we show similar results for all the 10 selected
sets. We follow here the same scheme of changing drug concentra-
tions as in Figure 4. We see that the α peaks of the full PSDs (here
shown in decibels by color) of the individual sets indeed follow the
“zigzag” shape we saw in the quantile bands of Figure 4. Panel III
in Figure 6 can be directly compared to Figure 5, which we have
just discussed. For example, Figure 5A corresponds to the first
phase in panel III here. Overall we see that while the sets clearly
change in a similar way, they all have individual features that set
them apart from the others. For example, parameter set IV shows
particularly strong changes in the low frequency range, whereas
parameter set VII reacts with a particularly strong lowering of the
α peak frequency in the presence of ketamine. These variations
can be considered as representing the variations that one can also
observe in humans.
DISCUSSION
We have shown that observed changes of the EEG α peak fre-
quency induced by the presence of the anesthetic agents propofol
and ketamine, but in particular also by their interaction when
given concurrently, can be explained based on the modeling of
HCN1-mediated hyperpolarizations alone, at least qualitatively.
This is surprising, since the main mechanism of action of these
drugs is supposed to be through NMDA antagonism (ketamine)
and GABAA agonism (propofol), respectively. However, since
HCN1-knockout mice are indeed less sensitive to the hypnotic
effects of both drugs (Chen et al., 2009), this would indicate that
the EEG remains useful as an indicator of anesthetic action. It
is perhaps interesting to note that while ketamine is famous for
its hallucinatory action (Wolff and Winstock, 2006), and hence
is considered a dissociative anesthetic agent, propofol as a classic
general anesthetic agent is also capable of inducing a range of hal-
lucinatory phenomena (Balasubramaniam and Park, 2003). Hence
it is possible that psychotropic HCN1-mediated effects are simply
masked behaviorally more by propofol’s GABAA agonism than by
ketamine’s NMDA antagonism, but that the EEG is particularly
sensitive to these underlying changes.
Only a fraction of all considered parameter sets (1,627 of the
73,454 parameter sets from Bojak and Liley (2005) proved “sta-
ble” under the HCN1-mediated hyperpolarization changes up to
−6 mV on both excitatory and inhibitory neurons. However, this
is at least partly due to the computational methods used here:
the eigenspectrum method (Bojak and Liley, 2005) can only be
used for “fixed point” dynamics. Rejected sets could follow the
FIGURE 6 | Power spectral densities for all 10 selected parameter sets
under drug variation. We use here the same four phases of drug variation
as in Figure 4, as indicated by the dotted lines and quantified by bars
below the main panels: first, P =0→1.2 linearly, while K =0. Then
K =0→1.4 linearly, while P =1.2. Next P =1.2→0, while K =1.4. Finally,
K =1.4→0, while P =0. Every panel corresponds to 1 of the 10 selected
parameter sets, as indicated by a white roman numeral. The PSD for one
specific (P, K ) combination is indicated in the panel by a colored vertical
line corresponding to frequencies from 0 to 20 Hz. Colors here indicate
decibels of the PSD, with dark red corresponding to large, green to
medium and dark blue to small values. (The “jet” colormap of Matlab has
been mapped for each panel individually, to the full range of PSD decibel
values shown in the panel.) A white dashed line indicates the α peak
frequency in the absence of drugs.
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same kind of drug-induced changes, but be inaccessible with our
method chosen for its computational speed. In principle it would
be desirable to carry out fully non-linear calculations instead, but
under extra-cortical noise input it takes about a minute to estimate
a sufficiently detailed and accurate power spectrum on a regular
PC. For the 121× 121 hyperpolarization changes of Figure 3 that
would lead to about 10 days of calculations even for a single para-
meter set – but we investigate here 73,454 different ones. The
eigenspectrum method is several orders of magnitude faster even
for a single neural mass. Yet we include here also effects due to
the spatial distribution of neural masses, see Eq. 11. The computa-
tional load scales roughly linearly with the number of integration
points for the eigenspectrum method, but roughly as a square for
an equivalent fully non-linear simulation based on spatial grids.
This increases the difference in computation speed even further.
Thus for the investigations carried out here only the eigenspec-
trum method proves practicable. In addition, limit cycle or chaotic
dynamics are often more representative of seizures or other patho-
logical brain states, which in clinical practice would lead to the
termination of the pharmacological intervention that we intend
to describe here. Other than by numerical simulation in every sin-
gle case, we do not know how to determine the characteristics of
the dynamics past the point of instability.
Furthermore, our current investigation does not include the
NMDA and GABAA actions commonly assumed to be dominant
in these drugs. We speculate that a more complete simulation
could allow the use of a larger fraction of the 73,454 parameter
sets, since these omitted actions can affect the required stabil-
ity. A prolongation of the inhibitory postsynaptic potentials due
to GABAA, for example, could suppress excessive excitation and
thus stabilize a parameter set. These neglected stabilizing effects
would increase also in due proportion to the agent concentration,
just as the potentially destabilizing hyperpolarizations we have
modeled here do. In order to obtain spectral changes that demon-
strate clearly the expected frequency shifts, we introduced three
further selection cuts, leaving us with only 10 parameter sets out
of the 1,627. Again we speculate that NMDA and GABAA actions
may ameliorate this reduction. If this is not the case, then this may
point to underlying correlations between neural parameters or
functional properties that were not considered in Bojak and Liley
(2005), but which now prove crucial for a realistic description.
Note that in terms of the hyperpolarizations, cf. Figures 3B,C, the
non-reactivity to propofol means that for the 10 selected parame-
ter sets an increase in the hyperpolarization of excitatory neurons
can be compensated by an increase in the hyperpolarization of
inhibitory neurons. This could suggest a particular intrinsic bal-
ance of excitation and inhibition maintaining functional stability
against extrinsic disturbances.
As is apparent from Figure 2, most of our 10 selected sets
have relatively high α peak frequencies. However, this simply
reflects an underlying bias in the original 73,454 parameter sets,
cf. Figure 8 in Bojak and Liley (2005); and we were able to lower
base α frequencies through the adjustment of a few parameters
(e.g., cortico-cortical connectivity N βlk ) within physiological lim-
its, without thereby qualitatively changing the relative frequency
shifts due to propofol and ketamine. Other spectral features that
could be selected for are also unlikely to affect the α frequency
shifts here qualitatively. The constraints used by Bojak and Liley
(2005) leave plenty of room for such adjustments: effectively only
four out of 14 system eigenvalues were used to establish the “1/f”
background and the α resonance. Adding a weak beta frequency
resonance to enhance realism, for example, would only require the
adjustment of two further system eigenvalues. Thus we expect that
our results here would hold true if one were to redo the parame-
ter space search of Bojak and Liley (2005) first with additional
constraints on the base power spectra. Finally, for concurrent
application of propofol and ketamine we predict increases of the
α peak frequency of around 2 Hz, falling short of the 4.7 Hz seen
experimentally (Hayashi et al., 2007; Tsuda et al., 2007). Yet our
calculations were for “steady state” concentrations, and for rapid
increases in dosage, as in the experimental injection of a single
ketamine bolus here, one often finds a more complex response
due the pharmacodynamics and transient neural responses. The
so-called biphasic responses to anesthetic agents (Kuizenga et al.,
1998, 2001) has received theoretical attention from several groups
(Bojak and Liley, 2005; Wilson et al., 2006; Molaee-Ardekani et al.,
2007; Hutt and Longtin, 2010; Steyn-Ross and Steyn-Ross, 2010),
see also the review in Foster et al. (2008). Hints of such a biphasic
response could be visible in Figure 5 of Tsuda et al. (2007), which
shows a significant drop of the α peak shift with time from the
initial 4.7 Hz to values around 2 Hz. However, this would have to
be disentangled from the decrease in ketamine concentration due
to natural clearance after the bolus. We intend to investigate all the
mentioned issues in future work.
We found that we could account for the heterogeneous effects
of ketamine on the EEG if we assumed that propofol and ket-
amine interacted in an infra-additive or antagonistic manner in
their inhibition of HCN1-mediated neuronal membrane hyperpo-
larization. While most anesthetic and sedative agents are reported
to interact synergistically ketamine is well-known to be a major
exception (Hendrickx et al., 2008). The interaction between ket-
amine and GABAA agonists (most sedative/anesthetic agents) to
produce hypnosis is reported to range from additivity to infra-
additivity/antagonism (Hendrickx et al., 2008). On the basis of the
limited clinical data available it appears that the GABAA agonist
propofol can interact infra-additively to produce a given hypnotic
endpoint. For instance Hui et al. (1995), in a study involving 180
female patients presenting for minor gynecological surgery, cal-
culated quantal dose-response curves for propofol and ketamine
administered alone and in combination. On the basis of logarith-
mic regression of a response surface model, it was first suggested
that the dose-response for the combination was best explained
by additivity, but on reanalysis (Hendrickx et al., 2008), by infra-
additivity (significantly so for immobility, as trend for hypnosis).
In apparent contradiction, Sakai et al. (1999) claim a significantly
additive interaction between propofol and ketamine for the end-
points of unresponsiveness to vocal command and the loss of
eyelash reflex. However, the former study determined the prob-
ability of a given hypnotic endpoint in response to single doses
of fixed proportions of ketamine and propofol, whereas the latter
gave continuous infusions of ketamine and propofol until a given
hypnotic endpoint was reached. Another study by Frizelle et al.
(1997) used smaller doses of ketamine and targeted a lower level
of sedation (rousable to verbal stimuli) with a bolus of propofol
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and ketamine followed by concomitant infusion. They found no
statistical evidence that the addition of ketamine reduced the
required amount of propofol to reach their intended sedation
level, suggesting once more infra-additivity. Clearly, additional
work regarding the pharmacodynamic interactions of ketamine
and propofol are required, as it is difficult to reconcile the results
of these studies.
The use of neural field/mass approaches to modeling drug
action on the EEG is emerging as a powerful explanatory frame-
work (Liley and Bojak, 2005; Foster et al., 2008; Hutt, 2011),
which is able to retain meaningful connections to the brain’s
physiology despite its mesoscopic scale of description. Because
neural field/mass models generally have much smaller parame-
ter and state spaces than biophysically plausible neural network
models, they are not only much easier to parameterize and simu-
late, but offer a simpler framework from which to make predictions
and derive hypotheses that can be empirically tested. Our ability
to account qualitatively for the effects that propofol and keta-
mine have on the EEG adds to a growing list of phenomena
that are amenable to neural field/mass description (Deco et al.,
2008; Coombes, 2010; Bressloff, 2012; Liley et al., 2012). Ulti-
mately it is hoped that by accounting for large scale phenomena
using neural field/mass models, genuine and enduring insights
into brain function and physiology will emerge.
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APPENDIX
Table A1 |The 10 selected parameter sets, whose PSDs are shown in Figure 2.
I II III IV V VI VII VIII IX X
hre (mV) −68.718 −70.286 −69.774 −78.169 −63.407 −60.745 −67.15 −64.128 −64.061 −60.588
hri (mV) −71.115 −78.148 −69.325 −79.978 −72.375 −70.488 −79.864 −79.399 −70.777 −69.941
τe (ms) 149.16 83.072 125.02 104.53 69.026 86.932 134.75 77.855 96.538 109.63
τi (ms) 125.78 122.72 116.58 112.75 118.65 50.200 66.766 137.77 43.662 76.350
heqee (mV) 1.8642 −16.433 3.2177 8.7034 −2.5551 1.9520 −18.571 −9.8354 8.4179 0.83573
heqei (mV ) −13.716 5.2227 8.2845 −14.231 −17.725 −15.828 −19.572 −4.4417 4.0220 2.4429
heqie (mV ) −86.369 −85.969 −86.775 −86.941 −85.466 −83.939 −86.449 −87.012 −82.833 −87.292
heqii (mV) −80.439 −85.348 −77.200 −86.445 −83.047 −79.708 −87.791 −87.906 −78.523 −78.755
Γee (mV) 0.22666 0.15856 0.17189 0.11073 0.25964 0.18606 0.31401 0.11187 0.10671 0.15192
Γei (mV) 0.72933 1.8661 1.7385 1.8429 1.7030 0.91706 1.7073 1.2797 0.60619 1.7838
Γie (mV) 1.9579 1.6800 1.5436 1.6612 1.8285 1.1699 0.53775 1.2751 0.31684 1.2942
Γii (mV) 1.0898 0.68575 0.61488 0.53105 0.87001 0.38026 0.10299 0.59535 0.38033 1.2539
γee (s−1) 768.09 979.20 626.91 494.19 399.13 848.11 964.40 795.80 689.20 355.38
γei (s−1) 128.26 399.71 357.24 170.95 246.39 219.24 238.50 191.63 224.39 258.87
γie (s−1) 192.29 178.41 135.36 411.10 251.74 82.043 468.53 221.95 133.21 203.10
γii (s−1) 57.060 58.091 52.773 53.437 49.217 50.113 43.132 57.302 59.581 49.348
Nβee 3393.0 2552.5 2337.7 4557.9 3571.9 2945.1 2002.9 3941.9 2061.2 2718.0
Nβei 4520.7 4183.2 4168.8 4922.0 4290.5 2771.2 3297.8 4833.0 4357.1 4964.4
Nβie 270.31 674.75 566.64 934.52 927.91 520.26 703.66 838.55 835.88 607.11
Nβii 125.69 453.59 594.80 141.53 472.96 658.36 294.98 890.80 314.72 147.19
Nαee 4223.4 2234.3 4974.3 2517.6 2871.9 2230.2 2678.3 2874.7 4781.7 4128.1
Nαei 2892.3 1559.1 2837.9 2412.1 2952.9 1441.3 1693.6 2896.0 2095.3 2078.7
Λ (cm−1) 0.69280 0.27742 0.2529 0.76041 0.16148 0.22388 0.84812 0.56276 0.83448 0.51625
ν (cm−1) 116.05 137.60 483.12 158.20 156.22 283.76 483.97 504.36 790.03 325.52
Smaxe (s
−1) 311.08 201.57 474.21 126.59 88.686 103.54 280.25 422.80 190.77 246.41
Smaxi (s
−1) 249.73 280.48 287.93 171.23 227.44 238.74 473.82 294.99 485.67 411.64
µ¯e (mV) −45.365 −49.195 −53.432 −54.004 −44.616 −46.851 −46.811 −43.850 −47.622 −51.391
µ¯i (mV) −49.046 −45.093 −51.480 −44.165 −48.954 −47.996 −51.395 −50.619 −42.285 −44.831
σˆe (mV) 6.5908 6.7284 5.2051 6.8209 6.9030 5.9824 5.9045 6.6268 5.6959 5.0919
σˆi (mV) 4.3224 4.7270 4.4501 4.1542 5.4314 3.0605 5.4229 5.8536 5.6195 6.6326
p¯ee (s−1) 7795.9 7344.6 7966.7 5876.2 4496.4 3882.5 6781.8 2649.9 9342.5 2833.6
pei (s−1) 329.39 2554.0 999.87 2120.3 2188.8 2337.9 1196.8 2063.5 914.37 1339.4
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